It certainly was a big week — with companies having to raise more than $100 million to make the list. Biotech- and healthcare ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Tenvie Therapeutics launches with $200M, acquires Denali drug candidates, led by Tony Estrada with NLRP3 and SARM1 inhibitors ...

Positive results from clinical trials often give biotechnology companies a boost, but this one was big. Shares of Sana Biotechnology —a firm with a market capitalization of less than $400 million as ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Acronis, a global leader in cybersecurity and data protection, is pleased to announce the appointment of Gerald Beuchelt as ...